WEMADE
Blockbuster MMORPG ‘NIGHT CROWS,’ a game published by Wemade and developed by MADNGINE, will begin pre-download on March 11th.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311799600/en/
Wemade's global version of 'NIGHT CROWS' opens pre-download on March 11th (Graphic: Wemade)
Users can download the PC and mobile versions in advance through the official website (https://www.nightcrows.com/en) until the official service on March 12th. The official service will launch at 1 PM (KST) on March 12th.
NIGHT CROWS is a cross-platform (PC/Mobile) MMORPG based on Unreal Engine 5. It features a 13th-century European world setting and storyline, high-quality graphics, and exhilarating battles using Gliders.
NIGHT CROWS implemented multi-tokenomics and character NFTs using blockchain technology.
Multi-tokenomics goes beyond the limitations of traditional single token-based tokenomics by consisting of a total of 7 multi-utility tokens minted with in-game assets and items. The key currency, CROW, can be used to purchase six in-game item tokens or traded on WEMIX PLAY. Utility tokens minted in the game can be exchanged or burned for CROW and then exchanged back for in-game items.
It also mints ‘Character NFTs,’ which include characters with extensive information such as character equipment and skills. The NFTs can be purchased or sold for CROW on WEMIX PLAY, providing a revolutionary experience where in-game economy is connected to the real world.
With the omnichain network, Wemade supports WEMIX3.0, Avalanche, BNB, Ethereum, Kroma, Polygon blockchain networks as well as una Wallet, WEMIX Wallet, and PLAY Wallet. Users on other chains can easily enjoy the advanced tokenomics of NIGHT CROWS.
More information on NIGHT CROWS can be found on its official website (https://www.nightcrows.com/en).
Meanwhile, the NFT collection ‘The Night is Coming’ released in January to celebrate the global pre-registration of NIGHT CROWS was sold out on the day of the release, fueling excitement for the global release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311799600/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management Launches First ELTIF to Expand Access to European Direct Lending Strategy19.6.2025 12:00:00 CEST | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the launch of its first European Long-Term Investment Fund (“ELTIF”) vehicle, the Ares European Strategic Income ELTIF Fund (“AESIF ELTIF”), a semi-liquid perpetual direct lending fund that will provide individual investors in the European Economic Area with expanded access to Ares’ leading European Direct Lending strategy. AESIF ELTIF is the latest offering through the wealth channel and its first under the updated ELTIF regime. Designed to deliver a diversified portfolio largely comprising directly originated, senior secured floating rate loans to businesses in Western Europe, AESIF ELTIF seeks to provide a durable income solution with downside protection and yield stability. AESIF ELTIF is intended to widen individual investor participation in Ares’ European Direct Lending strategy through lower investment minimums relative to traditional alternative investment product
LTIMindtree Launches ‘BlueVerse’ — An AI Ecosystem that will Define the Enterprise of the Future19.6.2025 11:30:00 CEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the launch of a new business unit and suite of AI services and solutions: BlueVerse. Designed as a complete AI ecosystem, it helps enterprises accelerate their AI concept-to-value journey. This ecosystem is a universe of components that enterprises need to elevate business operations, achieve breakthrough productivity, and create transformational customer experiences. BlueVerse Marketplace currently has over 300 industry and function-specific agents and ensures seamless interoperability and a growing connector ecosystem. It is underpinned by responsible AI governance, delivering enterprise-grade trust and scalability. BlueVerse Productized Services utilize repeatable frameworks, accelerators, and industry-specific solution kits. At launch, BlueVerse will offer pre-built solutions for Marketing Services and Contact Center as a Service (CCaaS). With Marketing Services busines
KIKO Milano Partners with Logistics Reply to Accelerate E-Commerce Delivery in the UK Market19.6.2025 10:00:00 CEST | Press release
Logistics Reply, the Reply group company specialising in innovative supply chain solutions has partnered with KIKO Milano, the global cosmetics brand renowned for its cutting edge, high-quality beauty products, to transform its e-commerce operations in the UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619841029/en/ This partnership represents a strategic milestone in KIKO’s broader digital transformation journey and reinforces its commitment to operational excellence and an exceptional customer experience. With rapid growth in the UK market and a rising demand for online shopping and fast home delivery, KIKO recognized the need to evolve its supply chain operations. To meet these challenges, KIKO opened a new dark store in London and selected Logistics Reply with its LEA Reply™ Warehouse Management System (WMS) to build a more scalable and agile logistics infrastructure. A dark store is a retail distribution centre t
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases19.6.2025 09:35:00 CEST | Press release
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative solutions for people living with rare diseases, today announced the recipients of its "Find For Rare" research grant program. The independently assessed, expert-led research grant initiative aims to improve patient care and management by recognising innovative research in three lysosomal diseases: Fabry disease, alpha-mannosidosis, and cystinosis. The selected projects demonstrated significant potential to address unmet needs within these rare communities. The recipients include: Fabry disease: Mitra Tavakoli, University of Exeter, Exeter, UK, for her project "FAB-PAIN: Precise phenotyping of neuropathy using a range of novel biomarkers in Fabry Disease” Project overview: This project aims to explore a range of novel biomarkers to better understand the pain pathways and its pathophysiology in Fabry disease. The findings may lead to the development of a range of new neuropathic biomarkers,
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy19.6.2025 09:15:00 CEST | Press release
Presented at EACR 2025, promising results show the impact of Brenus Pharma and InSphero’s collaboration in advancing translational immunotherapy through scalable 3D tumor models. Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer. Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorectal cancer spheroids using tumor cell lines co-cultured with fibroblasts. The vitrification method preserves morphology, stromal integrity, and viability after thawing, enabling realistic evaluation of STC-1010’s therapeutic potential under conditions mimicking in vivo human tumors. Previous studies showed that STC-1010 antigens were effectively processed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom